PAX3 and neoplasm: Low-coverage WGR of individuals showing tumor regression and those that succumbed to the disease enabled a genome-wide association study to be undertaken, which identified two genomic regions that may be associated with resistance to DFTD including PAX3 and TLL1 loci [78].